Lexaria Bioscience Expands Patent Portfolio with Five New Grants Including Diabetes Treatment Patents

Lexaria Bioscience Corp. has expanded its intellectual property portfolio with five new patents granted in Japan and Australia, including two specifically for diabetes treatments using GLP-1 drugs in conjunction with the company's proprietary DehydraTECH technology. The patents cover compositions and methods for treating hypertension, epilepsy, and diabetes, with terms extending through 2043 and 2044. According to CEO Richard Christopher, the diabetes-related patents represent a significant achievement given the competitive international landscape of the GLP-1 industry, where pharmaceutical companies are racing to develop effective treatments.

The company received two new patents in Japan for its hypertension treatment patent family, bringing the total to six granted patents across multiple jurisdictions for this therapeutic area. For epilepsy treatments, Lexaria secured one additional Australian patent, complementing existing patents in the United States and European Union. Most notably, the company obtained two new Australian patents for diabetes treatments, adding to its existing U.S. patents in this category. These diabetes patents specifically cover the use of DehydraTECH technology with already-approved GLP-1 drugs, potentially offering improved delivery methods for existing diabetes medications.

Lexaria's recent Phase 1b human study conducted in Australia provided supporting evidence for the capabilities of its DehydraTECH technology when combined with GLP-1 drugs. The study, referenced as GLP-1-H24-4, demonstrated the technology's potential to enhance drug delivery through oral administration. The company's research and development programs continue to focus on advancing commercial relationships while establishing valuable intellectual property across multiple international jurisdictions. Lexaria maintains a robust patent portfolio with 65 granted patents worldwide and additional applications pending.

The company's DehydraTECH technology platform improves how various drugs enter the bloodstream through oral delivery, potentially increasing bio-absorption while reducing side effects. This latest expansion of Lexaria's patent portfolio strengthens its position in competitive pharmaceutical markets, particularly in the rapidly evolving diabetes treatment sector where GLP-1 drugs have gained significant attention. The company expects to receive additional patent awards in the future as its research initiatives continue. More information about the company's technology and research can be found at https://www.lexariabioscience.com.